Investigational Drug Treatments for Triple-Negative Breast Cancer

Investigational Drug Treatments for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which...

Full description

Bibliographic Details
Main Authors: Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Konstantinos Nikolettos, Panagiotis Sarantis, Vasiliki E. Georgakopoulou, Afroditi Nonni, Dimitrios Schizas, Efstathios A. Antoniou, Michalis V. Karamouzis, Nikos Nikolettos, Konstantinos Kontzoglou, Alexandros Patsouras, Errika Voutyritsa, Athanasios Syllaios, Evangelos Koustas, Nikolaos Trakas, Dimitrios Dimitroulis
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Personalized Medicine
Subjects:
novel therapeutic strategies
immunotherapy
targeted therapies
PI3kb/mTOR inhibitors
PARP inhibitors
histone deacetylase inhibitors
Online Access:https://www.mdpi.com/2075-4426/11/7/652
id doaj-af5ec79de8e846528f18606cce12df26
record_format Article
spelling doaj-af5ec79de8e846528f18606cce12df262021-07-23T13:49:32ZengMDPI AGJournal of Personalized Medicine2075-44262021-07-011165265210.3390/jpm11070652Investigational Drug Treatments for Triple-Negative Breast CancerChristos Damaskos0Nikolaos Garmpis1Anna Garmpi2Konstantinos Nikolettos3Panagiotis Sarantis4Vasiliki E. Georgakopoulou5Afroditi Nonni6Dimitrios Schizas7Efstathios A. Antoniou8Michalis V. Karamouzis9Nikos Nikolettos10Konstantinos Kontzoglou11Alexandros Patsouras12Errika Voutyritsa13Athanasios Syllaios14Evangelos Koustas15Nikolaos Trakas16Dimitrios Dimitroulis17Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceFirst Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceDepartment of Pulmonology, Laiko General Hospital, 11527 Athens, GreeceFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceFirst Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceObstetric-Gynecologic Clinic, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceFirst Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceDepartment of Biochemistry, Sismanogleio Hospital, 15126 Athens, GreeceSecond Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.https://www.mdpi.com/2075-4426/11/7/652novel therapeutic strategiesimmunotherapytargeted therapiesPI3kb/mTOR inhibitorsPARP inhibitorshistone deacetylase inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Christos Damaskos
Nikolaos Garmpis
Anna Garmpi
Konstantinos Nikolettos
Panagiotis Sarantis
Vasiliki E. Georgakopoulou
Afroditi Nonni
Dimitrios Schizas
Efstathios A. Antoniou
Michalis V. Karamouzis
Nikos Nikolettos
Konstantinos Kontzoglou
Alexandros Patsouras
Errika Voutyritsa
Athanasios Syllaios
Evangelos Koustas
Nikolaos Trakas
Dimitrios Dimitroulis
spellingShingle Christos Damaskos
Nikolaos Garmpis
Anna Garmpi
Konstantinos Nikolettos
Panagiotis Sarantis
Vasiliki E. Georgakopoulou
Afroditi Nonni
Dimitrios Schizas
Efstathios A. Antoniou
Michalis V. Karamouzis
Nikos Nikolettos
Konstantinos Kontzoglou
Alexandros Patsouras
Errika Voutyritsa
Athanasios Syllaios
Evangelos Koustas
Nikolaos Trakas
Dimitrios Dimitroulis
Investigational Drug Treatments for Triple-Negative Breast Cancer
Journal of Personalized Medicine
novel therapeutic strategies
immunotherapy
targeted therapies
PI3kb/mTOR inhibitors
PARP inhibitors
histone deacetylase inhibitors
author_facet Christos Damaskos
Nikolaos Garmpis
Anna Garmpi
Konstantinos Nikolettos
Panagiotis Sarantis
Vasiliki E. Georgakopoulou
Afroditi Nonni
Dimitrios Schizas
Efstathios A. Antoniou
Michalis V. Karamouzis
Nikos Nikolettos
Konstantinos Kontzoglou
Alexandros Patsouras
Errika Voutyritsa
Athanasios Syllaios
Evangelos Koustas
Nikolaos Trakas
Dimitrios Dimitroulis
author_sort Christos Damaskos
title Investigational Drug Treatments for Triple-Negative Breast Cancer
title_short Investigational Drug Treatments for Triple-Negative Breast Cancer
title_full Investigational Drug Treatments for Triple-Negative Breast Cancer
title_fullStr Investigational Drug Treatments for Triple-Negative Breast Cancer
title_full_unstemmed Investigational Drug Treatments for Triple-Negative Breast Cancer
title_sort investigational drug treatments for triple-negative breast cancer
publisher MDPI AG
series Journal of Personalized Medicine
issn 2075-4426
publishDate 2021-07-01
description Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.
topic novel therapeutic strategies
immunotherapy
targeted therapies
PI3kb/mTOR inhibitors
PARP inhibitors
histone deacetylase inhibitors
url https://www.mdpi.com/2075-4426/11/7/652
work_keys_str_mv AT christosdamaskos investigationaldrugtreatmentsfortriplenegativebreastcancer
AT nikolaosgarmpis investigationaldrugtreatmentsfortriplenegativebreastcancer
AT annagarmpi investigationaldrugtreatmentsfortriplenegativebreastcancer
AT konstantinosnikolettos investigationaldrugtreatmentsfortriplenegativebreastcancer
AT panagiotissarantis investigationaldrugtreatmentsfortriplenegativebreastcancer
AT vasilikiegeorgakopoulou investigationaldrugtreatmentsfortriplenegativebreastcancer
AT afroditinonni investigationaldrugtreatmentsfortriplenegativebreastcancer
AT dimitriosschizas investigationaldrugtreatmentsfortriplenegativebreastcancer
AT efstathiosaantoniou investigationaldrugtreatmentsfortriplenegativebreastcancer
AT michalisvkaramouzis investigationaldrugtreatmentsfortriplenegativebreastcancer
AT nikosnikolettos investigationaldrugtreatmentsfortriplenegativebreastcancer
AT konstantinoskontzoglou investigationaldrugtreatmentsfortriplenegativebreastcancer
AT alexandrospatsouras investigationaldrugtreatmentsfortriplenegativebreastcancer
AT errikavoutyritsa investigationaldrugtreatmentsfortriplenegativebreastcancer
AT athanasiossyllaios investigationaldrugtreatmentsfortriplenegativebreastcancer
AT evangeloskoustas investigationaldrugtreatmentsfortriplenegativebreastcancer
AT nikolaostrakas investigationaldrugtreatmentsfortriplenegativebreastcancer
AT dimitriosdimitroulis investigationaldrugtreatmentsfortriplenegativebreastcancer
_version_ 1721287601027022848

Similar Items